Dr. Jorge Leon, an Industry Leader in Molecular Diagnostics, Joins CytoCore's Medical Advisory Board

Business Wire, April 27, 2006

CHICAGO -- CytoCore, Inc. (OTCBB:MCDG) announces the engagement of Dr. Jorge A. Leon, Ph.D., as a member of the Medical Advisory Board and his company, Leomics Associates, as consultants to CCI.

Dr. Leon has a Ph.D. in Cellular and Molecular Biology. Dr. Leon was one of the founders of the Molecular Diagnostic and Applied Genomics business at Quest Diagnostics where as their VP of applied genomics, he helped build and drove the strategy for Quest Diagnostics Molecular Diagnostics business, now the largest in the country.

Dr. Leon is recognized internationally within the investment and scientific communities as an industry leader for molecular diagnostics. Presently he is founder and President of Leomics Associates, Inc., a consulting company that develops diagnostic strategies for companies that want to enter the diagnostics space. Dr Leon has over twenty years of experience in evaluating, developing and commercializing new technologies and scientific innovations into successful diagnostic products. He is the holder of several patents, has been published extensively, and serves on the Board of various leading edge technology companies.

CytoCore's CEO, Dr. David Weissberg said: "We are delighted in this new relationship with Dr. Jorge Leon and Leomics. Dr. Leon brings a depth of real world business experience and credibility in the commercialization of new diagnostic products. Dr. Leon's experience, business background and contacts should help inform and guide CytoCore's strategic decisions and the current plans for each of CCI's products. With the e2 Collector ready for pre-manufacturing tooling, Dr. Leon will be able to assist us in meeting appropriate distribution partners to bring the Collector to the widest audience of users. Given Dr. Leon's extensive experience and perspective in the Biomolecular and Diagnostic sectors we anticipate his support and guidance with the introduction of the P2X7 biomarker to the cervical and endometrial cancer screening marketplace. Dr. Leon is familiar with CytoCore's technology portfolio, and he is ready to help bring these valuable and lifesaving products to the marketplace."

Dr. Leon commented, "I am very excited with the opportunity to participate on CytoCore's Medical Advisory Board. I've been watching this technology for some time. The science from Dr. Gorodeski's lab is scientifically sound, published in first tier peer reviewed journals, and has great potential in unmet applications in diagnostics and drug delivery. I am especially excited about the application of CytoCore's technology platform and biomarkers in developing countries where the conventional, more expensive diagnostic methods for cervical cancer and other cancers are not fully implemented or effective. If the P2X7 marker proves itself with further testing to be consistently accurate with the initial lab tests, this marker will be a major advancement in screening for cervical and endometrial cancer. I am looking forward to contributing to the development and commercialization of CytoCore's unique mix of life saving medical technologies."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005 and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.